Stem cell transplant reviewed for peripheral T-cell lymphoma
Giving a voice to child victims of family abuse and neglect
10 June 2021Study shows how certain macrophages dampen anti-tumor immunity
10 June 2021Stem cell transplant reviewed for peripheral T-cell lymphoma
(HealthDay)—For patients with refractory or relapsed peripheral T-cell lymphoma (R/R-PTCL), three- and five-year overall survival (OS) and progression-free survival (PFS) are similar with allogeneic or autologous hematopoietic stem cell transplant (HSCT), but transplant-related mortality (TRM) is higher with allogeneic HSCT, according to a review published online May 27 in JAMA Network Open.
